拉米夫定对慢性乙肝患者HBV-DNA及HBeAg的阴转作用

目的：探讨拉米夫定治疗前后慢性乙肝患者血清及周围血单个核细胞（PBMCs）内HBV-DNA及HBeAg的变化。方法：用ELISA检测患者血清标志物;用荧光定量PCR检测患者血清及PBMCs内HBV-DNA的含量。拉米夫定对病人进行治疗,12周为一疗程,共4个疗程。结果：拉米夫定治疗48周后HBeAg及血清、PBMCs内HBV-DNA阴转率分别为52.31、46.15、41.82,较常规治疗组差异具有显著性（P〈0.05）。结论：拉米夫定对慢性乙肝患者HBV-DNA、HBeAg有较好的转阴率,且PBMCs内HBV-DNA的检测是鉴定拉米夫定疗效的一个重要指标,对抗病毒治疗具有明显的指导意义。

Therapeutic Sero-Conversion(HBV-DNA,HBeAg) Effect of Lamivudine in Patients with Chronic Hepatits B

Objective To study the changes of positive rate of serum HBV-DNA and HBeAg as well as peripheral blood mononuclear cell(PBMC) HBV-DNA after lamivudine therapy in patients with hapatitis B.Methods Sixty-five serum HBV-DNA(and HBeAg) positive HBV-hepatitis patients(of which 55 were also intra PBMC HBV-DAN positive) were treated with lamivudine(100mg/d) for 48 weeks.Thirty patients(of which 24 were intra-PBMC HBV-DNA positive) without anti-viral therapy served as controls.Serum and PBMC HBV-DNA(with FQ-PCR) as...